Loading…
The effect of fecal microbiota transplantation (FMT) on the successful integration of microbiota in individuals with metabolic syndrome remains unclear.
It is a randomized placebo-controlled clinical trial to study Fecal Microbiota Transplantation (FMT) + Lifestyle intervention (LSI) or Fecal Microbiota Transplantation (FMT) or Lifestyle intervention (LSI) in 61 randomized patients with adiposity / obesity (BMI >=28 kg/m^2 and < 45 kg/m^2^) and Type 2 Diabetes (T2D)
Proportion of subjects acquiring ≥20% of microbiota from lean donors at week 24
At week 24, the proportions of subjects acquiring 20% or more of lean-associated microbiota were 100% in the FMT plus LSI group, 88.2% in the FMT alone group, and 22% in the sham plus LSI group, with a significance level of p<0.0001. The repeated administration of FMTs significantly enhanced the engraftment of lean-associated microbiota, with a significance level of p<0.05. Both FMT with and without LSI resulted in an increase in butyrate-producing bacteria. The combination of LSI and FMT led to a greater increase in Bifidobacterium and Lactobacillus compared to FMT alone, with a significance level of p<0.05. Additionally, the FMT plus LSI group experienced a reduction in total and low-density lipoprotein cholesterol, as well as liver stiffness, at week 24 compared to baseline, with a significance level of p<0.05.
Repeated FMTs increase both the level and duration of microbiota engraftment in obese patients with T2DM. When combined with lifestyle intervention, FMT results in more favorable changes in the recipients' microbiota, as well as improvements in lipid profile and liver stiffness.